Electrochemical Probing of Human Liver Subcellular S9 Fractions for Drug Metabolite Synthesis
-
Published:2024-08-03
Issue:8
Volume:14
Page:429
-
ISSN:2218-1989
-
Container-title:Metabolites
-
language:en
-
Short-container-title:Metabolites
Author:
Medina Daphne1, Omanakuttan Bhavana1, Nguyen Ricky1, Alwarsh Eman1, Walgama Charuksha1ORCID
Affiliation:
1. Department of Physical & Applied Sciences, University of Houston-Clear Lake, 2700 Bay Area Boulevard, Houston, TX 77058, USA
Abstract
Human liver subcellular fractions, including liver microsomes (HLM), liver cytosol fractions, and S9 fractions, are extensively utilized in in vitro assays to predict liver metabolism. The S9 fractions are supernatants of human liver homogenates that contain both microsomes and cytosol, which include most cytochrome P450 (CYP) enzymes and soluble phase II enzymes such as glucuronosyltransferases and sulfotransferases. This study reports on the direct electrochemistry and biocatalytic features of redox-active enzymes in S9 fractions for the first time. We investigated the electrochemical properties of S9 films by immobilizing them onto a high-purity graphite (HPG) electrode and performing cyclic voltammetry under anaerobic (Ar-saturated) and aerobic (O2-saturated) conditions. The heterogeneous electron transfer rate between the S9 film and the HPG electrode was found to be 14 ± 3 s−1, with a formal potential of −0.451 V vs. Ag/AgCl reference electrode, which confirmed the electrochemical activation of the FAD/FMN cofactor containing CYP450-reductase (CPR) as the electron receiver from the electrode. The S9 films have also demonstrated catalytic oxygen reduction under aerobic conditions, identical to HLM films attached to similar electrodes. Additionally, we investigated CYP activity in the S9 biofilm for phase I metabolism using diclofenac hydroxylation as a probe reaction and identified metabolic products using liquid chromatography–mass spectrometry (LC-MS). Investigating the feasibility of utilizing liver S9 fractions in such electrochemical assays offers significant advantages for pharmacological and toxicological evaluations of new drugs in development while providing valuable insights for the development of efficient biosensor and bioreactor platforms.
Funder
Welch Foundation U.S. Department of Education National Science Foundation
Reference44 articles.
1. An overview of drug discovery and development;Berdigaliyev;Future Med. Chem.,2020 2. Human disease models in drug development;Loewa;Nat. Rev. Bioeng.,2023 3. Natural products in drug discovery: Advances and opportunities;Atanasov;Nat. Rev. Drug Discov.,2021 4. Thomford, N.E., Senthebane, D.A., Rowe, A., Munro, D., Seele, P., Maroyi, A., and Dzobo, K. (2018). Natural Products for Drug Discovery in the 21st Century: Innovations for Novel Drug Discovery. Int. J. Mol. Sci., 19. 5. Zhao, M., Ma, J., Li, M., Zhang, Y., Jiang, B., Zhao, X., Huai, C., Shen, L., Zhang, N., and He, L. (2021). Cytochrome P450 Enzymes and Drug Metabolism in Humans. Int. J. Mol. Sci., 22.
|
|